Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy

Area of Science:

• Oncology
• Infectious Diseases
• Immunology

Background:

• Highly active antiretroviral therapy (HAART) introduction has been linked to reduced lymphoma incidence in HIV-infected individuals.
• AIDS-related lymphoma remains a significant concern, with evolving epidemiological and etiological factors.

Purpose of the Study:

• To investigate clinicopathological changes in AIDS-related lymphoma in Tokyo from 1987 to 2005.
• To assess the impact of HAART on lymphoma subtypes, viral associations, and disease involvement patterns.

Main Methods:

• A clinicopathological study of 86 AIDS-related lymphoma patients.
• Analysis of autopsy data (incidence: 27%) and histological subtypes, including Diffuse large B cell lymphoma and Burkitt's lymphoma.
• Evaluation of Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) prevalence, and changes in nodal and central nervous system involvement.

Main Results:

• Diffuse large B cell lymphoma was the predominant subtype (78%).
• Burkitt's lymphoma (BL) incidence increased in the HAART era (13%), while EBV-positive lymphoma decreased (58%).
• Nodal involvement rose (50%), and central nervous system involvement decreased (38%) in the HAART era.

Conclusions:

• HAART may play a partial role in observed changes in AIDS-related lymphoma.
• Alterations in immunological backgrounds, particularly EBV prevalence, are suggested as a leading cause for these shifts.
• Further research into the interplay between HAART, immune status, and specific lymphoma types is warranted.